View Cart  

Idenix Confident in Safety Advantage of Hep C Drug Despite Trial Hold

A A
Idenix remains confident that its lead product candidate, hepatitis C drug IDX184, has a safety advantage over a similar Bristol-Myers Squibb (BMS) competitor despite a partial clinical hold placed on IDX184 following adverse heart events seen in BMS’ trials.

To View This Article:

Login

Subscribe To Drug Industry Daily